American Century Companies Inc. Has $55.92 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO

American Century Companies Inc. decreased its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 1.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,076,586 shares of the company’s stock after selling 13,548 shares during the quarter. American Century Companies Inc. owned approximately 0.56% of BridgeBio Pharma worth $55,918,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its stake in BridgeBio Pharma by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 16,832,059 shares of the company’s stock valued at $874,257,000 after buying an additional 347,074 shares during the last quarter. Geode Capital Management LLC boosted its holdings in BridgeBio Pharma by 5.1% during the second quarter. Geode Capital Management LLC now owns 3,681,580 shares of the company’s stock valued at $158,991,000 after acquiring an additional 178,686 shares during the period. Invesco Ltd. grew its position in shares of BridgeBio Pharma by 27.0% in the second quarter. Invesco Ltd. now owns 2,801,065 shares of the company’s stock valued at $120,950,000 after purchasing an additional 594,902 shares during the last quarter. Norges Bank bought a new position in shares of BridgeBio Pharma in the second quarter worth about $84,488,000. Finally, Principal Financial Group Inc. increased its stake in shares of BridgeBio Pharma by 23.0% in the third quarter. Principal Financial Group Inc. now owns 1,267,412 shares of the company’s stock worth $65,829,000 after purchasing an additional 236,885 shares during the period. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Morgan Stanley raised their target price on BridgeBio Pharma from $96.00 to $98.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Wells Fargo & Company increased their price objective on BridgeBio Pharma from $88.00 to $98.00 and gave the company an “overweight” rating in a research report on Friday, February 13th. Leerink Partners raised their price objective on shares of BridgeBio Pharma from $75.00 to $86.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. TD Cowen reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research report on Monday, January 12th. Finally, Barclays assumed coverage on shares of BridgeBio Pharma in a research note on Wednesday, January 28th. They set an “overweight” rating for the company. Twenty-two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $82.50.

Insider Buying and Selling

In other BridgeBio Pharma news, Director Randal W. Scott sold 10,000 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $75.46, for a total transaction of $754,600.00. Following the sale, the director directly owned 11,589 shares of the company’s stock, valued at approximately $874,505.94. The trade was a 46.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Thomas Trimarchi sold 13,600 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $74.72, for a total value of $1,016,192.00. Following the completion of the transaction, the chief financial officer directly owned 336,585 shares of the company’s stock, valued at approximately $25,149,631.20. The trade was a 3.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 164,174 shares of company stock valued at $12,036,335 over the last ninety days. Company insiders own 18.20% of the company’s stock.

BridgeBio Pharma Price Performance

Shares of BridgeBio Pharma stock opened at $66.17 on Friday. BridgeBio Pharma, Inc. has a 52-week low of $28.33 and a 52-week high of $84.94. The firm has a market capitalization of $12.83 billion, a PE ratio of -17.51 and a beta of 1.13. The company’s fifty day moving average price is $73.85 and its two-hundred day moving average price is $65.11.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Tuesday, February 24th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The firm had revenue of $154.18 million for the quarter, compared to analyst estimates of $150.71 million. The business’s quarterly revenue was up 2521.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.40) EPS. Analysts predict that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.